[1] Masahiro M,Yasuyoshi K,Eiko K,et al. Targeted disruption of NP95 gene renders murine embryonic stem cells hypersensitive to DNA damaging agents and DNA replication blocks[J]. J Biol Chem,2002,277(37): 34549-34555.[2] Masahiro M,Akira F,Mituru N,et al. Isolation and characterization of a novel human radiosusceptibility gene, NP95[J]. Radiat Res,2006,166(5): 723-733.[3] Bronner C,Achour M,Arima Y,et a1. The UHRF family: oncogenes that are drugable targets for cancer therapy in the near future?[J]. Pharmacol Ther,2007,115(3): 419-434.[4] Ian Marc B,Lucia L,Roberto P,et al. NP95 is regulated by E1A during mitotic reactivation of terminally differentiated cells and is essential for S phase entry[J]. J Cell Biol,2002, 157(6): 909-914.[5] Masahiko M,Hiroshi W,Takehito S,et al. Dynamic changes in subnuclear NP95 location during the cell cycle and its spatial relationship with DNA replication foci[J]. Exp Cell Res,2001,263(2): 202-208.[6] Sharif J,Muto M,Takebayashi S,et al. The SRA protein NP95 mediates epigenetic inheritance by recruiting dnmtl to methylated DNA[J]. Nature,2007,450(7171): 908-909.[7] Sharif J,Muto M. Recruitment of Dnmt1 roles of the SRA protein Np95 (UHRF1) and other factors[J]. Prog Mol Biol Transl Sci,2011,101(3):289-310.[8] Mousli M,Hopfner R,Abbady AQ,et a1. ICBP90 belongs to a new family of proteins with an expression that is deregulated in cancer cells[J]. British J Cancer,2003,89(1):120-127.[9] Li XL,Meng QH,Fan SJ. Adenovirus-mediated expression of UHRF1 reduces the radiosensitivity of cervical cancer HeLa cells to γ-irradiation[J]. Acta Pharmacol Sin,2009, 30(4):458-466.[10] Marianne L,Stephanie C,Christian B,et a1. Cell cycle and/or proliferation markers: what is the best method to discriminate cervical high-grade lesions?[J]. Hum Pathol, 2005,36(10):1101-1107.[11] Pi JT,Lin Y,Quan Q,et al. Overexpression of UHRF1 is significantly associated with poor prognosis in laryngeal squamous cell carcinoma[J]. Med Oncol,2013, 30(4):613.[12] Crnogorac-Jurcevic T,Gangeswaran R,Bhakta V,et al. Proteomic analysis of chronic pancreatitis and pancreatic adenocarcinoma [J]. Gastroenterology,2005,129(5):1454-1463.[13] Unoki M,Daigo Y,Koinuma J,et a1.UHRF1 is a novel diagnostic marker of lung cancer[J].British Cancer,2010, 103(2):217-222.[14] Unoki M,Kelly JD,Neal DE,et a1.UHRF1 is a novel molecular marker for diagnosis and the prognosis of bladder cancer[J].British Cancer,2009,101(1):98-105.[15] Hopfner R,Mousli M,Oudet P,et al. Overexpression of ICBP90,a novel CCAAT-binding protein,overcomes cell contact inhibition by forcing topoisomeraseⅡalpha expression[J]. Anti-cancer Res,2002,22(6A):3165-3170.[16] Quan ZW,Yang Y,Li JY,et al. The mechanisms of somatostatin induced enhanced chemosensitivity of gallbladder cancer cell line to doxorubicin: cell cycle modulation plus target enzyme up-regulation[J]. Biomed Pharmacother,2010, 64(7):451-457.[17] Jenkins Y,Markovtsov V,Lang W,et al. Critical role of the ubiquitin ligase activity of NP95,a nuclear RING finger protein,in tumor cell growth[J]. Mol Biol Cell,2005, 16(12): 5621-5629.[18] Daskalos A,Oleksiewicz U,Filia A,et al. UHRF1-mediated tumor suppressor gene inactivation in nonsmall cell lung cancer[J]. Cancer,2011,117(5):1027-1037.[19] Arima Y,Hirota T,Bronner C,et al. Down-regulation of nuclear protein ICBP90 by p53/p21Cip1/WAF1-dependent DNA-damage checkpoint signals contributes to cell cycle arrest at G1/S transition[J]. Genes Cells,2004,9(2):131-142.[20] Trotzier MA,Bronner C,Bathami K,et al. Phosphorylation of ICBP90 by protein kinase a enhances topoisomerase Ⅱ alpha expression[J]. Biochem Biophys Commun,2004,19(2):590-595.[21] Jeanblanc M,Mousli M,Hopfner R,et al. The retinoblastoma gene and its product are targeted by ICBP90: a key mechanism in the G1/S transition during the cell cycle[J]. Oncogene, 2005,24(49):7337-7345.[22] Bianchi C,Zangi R. UHRF1 discriminates against binding to fully-methylated CpG-sites by steric repulsion[J]. Biophys, 2013,171(1):38-45.[23] Abdul-Qader A,Christian B,Marie-A1ine T,et al. ICBP90 expression is downregulated in apoptosis-induced jurkat cells[J]. Ann NY Acad Sci,2003,1010(3):300-303.[24] Li X,Meng Q,Rosen EM,et al. UHRFl confers radio-resistance to human breast cancer cells[J].Int J Radiat Biol,2011,87(3):263-273.[25] Hoglund M,Gorunova L,Andren-Sandberg A,et al. Cytogenetand fluorescence in situ hybridization analyses of chromosome 19 aberrations in pancreatic carcinomas: frequent loss of 19p13.3 and gain of 19q13.1-13.2[J].Genes Chromo-somes Cancer,1998,21(1):8-16.[26] Sherer ME,Shekhter-Levin S,Krause JR,et al. Atypical (7∶19) translocation in acute myelomonocytic leukemia cancer genet[J]. Cytogenet,1991,57(2):169-173.[27] Gruber SB,Entius MM,Petersen GM,et al. Pathogenesis of adenocarcinoma in Peutz-Jeghers syndrome[J]. Cancer Res, 1998,58(23):5267-5270.[28] Achour M,Jacq X,Ronde P,et al.The interaction of the SRA domain of ICBP90 with a novel domain of DNMT1 is involved in the regulation of VEGF gene expression[J]. Oncogene,2008,27(15):2187-2197.[29] Michael J,Marc M,Raphael H,et al. The retinoblastoma gene and its product are targeted by ICBP90: a key mechanism in the G1/S transition during the cell cycle[J]. Oncogene, 2005,24(49):7337-7345.[30] Un F,Oi C,Prosser M,et al. Modulating ICBP90 to suppress human ribonucleotide reductase M2 induction restores sensitivity to hydroxyurea cytotoxicity[J].Anticancer Res,2006, 26 (4B):2761-2767.[31] Muto M,Kanari Y,Kubo E,et al. Targeted disruption of NP95 gene renders murine embryonic stem cells hypersensitive to DNA damaging agents and DNA replication blocks[J]. J Biol Chem,2002,277(37):34549-34555.